Who is the manufacturer of brigatinib/brigatinib?

Brigatinib/Brigatinib (Brigatinib) is a treatment drug specifically for non-small cell lung cancer (NSCLC) caused by ALK (tyrosine kinase) mutations. The drug was developed by Ariad Pharmaceuticals, an important subsidiary of Takeda Pharmaceutical Co., Ltd. In April 2017, brigatinib received accelerated approval from the U.S. Food and Drug Administration (FDA) for metastatic non-small cell lung cancer, opening the door to its clinical application. In 2020, it was further approved as a first-line treatment for patients with ALK-positive metastatic non-small cell lung cancer and is marketed under the trade name Alunbrig.

Brigatinib is an outstanding innovation from Ariad Pharmaceuticals that has demonstrated significant clinical efficacy in the treatment of non-small cell lung cancer caused by ALK mutations. The drug's mechanism of action is to effectively block the growth and reproduction of tumor cells by inhibiting the activation of ALK fusion protein, providing a new approach for the treatment of non-small cell lung cancer. It has been verified by clinical trials that brigatinib can significantly extend the progression-free survival of patients with non-small cell lung cancer, and has also shown good efficacy in the face of drug resistance. This makes brigatinib occupy a pivotal position in the treatment of non-small cell lung cancer.

Brigatinib is a prescription drug, and before starting treatment, doctors will conduct detailed testing of a patient's cancer to ensure that it has genetic mutations that affectALK, known as "ALK-positive" status. Brigatinib is available in 30 mg, 90 mg and 180 mg tablet strengths. Treatment can continue as long as the patient continues to benefit from treatment. If side effects occur during treatment, the doctor may adjust the drug dose or temporarily interrupt treatment depending on the specific situation.